A randomized controlled trial to compare a 1-dose vs 2-dose priming schedule of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian infants


Assess if a reduced dosing schedule of PCV13 (1+1) is non-inferior to the currently-used schedule (2+1) with regards to serotype-specific IgG concentration following booster dose at age 12 months. Outcome measures will be:

  1. Serotype-specific anti-pneumococcal IgG geometric mean concentration (GMC)
  2. Proportion of children achieving IgG ≥0.35 μg/ml at 1 month after (i) infant priming dose(s) and (ii) the age 12-month booster dose.

Project Lead:
Dr. Manish Sadarangani